Ampio Pharmaceuticals appoints Dan Stokely CFO

Thursday July 11, 2019 0 comments Tags: Englewood, Ampio Pharmaceuticals, Dan Stokely, Michael Macaluso

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, announced Dan Stokely has been appointed chief financial officer.Ampio_logoUSE

"As we are already dosing patients in our pivotal Phase III trial of Ampion, as a biological treatment for adults with pain due to severe osteoarthritis of the knee (OAK), we sought a seasoned CFO with the experience and skills to advise us as we continue to move toward a future commercialization of Ampion,” said Michael Macaluso, Ampio CEO.

Stokely has more than 30 years of experience in finance and accounting and is a certified public accountant. He began his career at Deloitte & Touche and since that time, has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies.

Most recently, since 2012, Stokely served as executive VP and CFO of Sentynl Therapeutics, a privately-held specialty pharmaceutical company focused on in-licensing, acquisition, marketing and distribution of development stage and commercially marketed prescription products, which was sold to Cadila Healthcare Ltd. in January 2017.

From 2004 to 2012, he served as VP of finance and chief accounting officer of Victory Pharma, a privately-held specialty pharmaceutical company focused on in-licensing, internal product development, marketing and distribution of pain specialty products, which was sold to Shionogi, Inc., a Japanese pharmaceutical company, in 2011. 

From 2001 to 2004, Stokely served as corporate controller and chief accounting officer for Wireless Facilities, Inc. (currently Kratos Defense & Security Solutions), a publicly traded, global provider of communications and security services for the wireless communications industry. 

From 1994 to 2001, he served as corporate controller of Dura Pharmaceuticals, a publicly traded pharmaceutical company that was sold to Elan Pharmaceuticals in late 2000. Stokely has a bachelor's degree in accounting from San Diego State University.